Introduction
The progress of cells through G 1 and into S phase is regulated by the activity of the retinoblastoma tumour suppressor protein (pRb) (Hiebert et al., 1992; Weinberg, 1995; Hall and Peters, 1996; Kaelin, 1999) . Mitogenic stimulation of quiescent cells promotes the expression of D-type cyclins, which assemble with their catalytic partners, CDK4 and CDK6 (Hall and Peters, 1996; Ekholm and Reed, 2000) . These cyclin D/CDK complexes initiate the phosphorylation of pRb, which relieves the transcriptional repression of the cyclin E gene (Zhang et al., 2000) . Subsequent expression of cyclin E and assembly of cyclin E/CDK2 complexes promotes further phosphorylation of pRb, causing the release of E2F and expression of E2F-regulated genes that are required for the initiation of S phase, including cyclin A (Knudsen and Wang, 1997; Dyson, 1998; Helin, 1998; Knudsen et al., 1998) .
CDKs are also regulated by phosphorylation (Gu et al., 1992; Clarke, 1995) . Activation of CDK4 and CDK2 requires the phosphorylation of a conserved threonine residue within the catalytic loop and dephosphorylation of Thr14 and Tyr15 in the ATP-binding pocket. Dephosphorylation of CDK2 is catalysed by Cdc25A, a dual specificity phosphatase, that is expressed during the G 1 and S phases (Jinno et al., 1994; Blomberg and Hoffmann, 1999) .
CDK activity is inhibited by the actions of small molecular weight CDK inhibitors (CDKIs) . The INK4 family CDKIs (e.g. p16
INK4a
) specifically inhibit CDK4 and CDK6, whereas the CIP/ KIP family members (e.g. p27 KIP1 and p21 CIP1 ) bind and inhibit cyclin/CDK2 complexes. In quiescent cells, high p27 KIP1 levels restrain cell cycle re-entry by inhibiting cyclin E/CDK2 complexes, whereas mitogenic signals promote ubiquitin-mediated degradation or proteolytic processing of p27 KIP1 (Pagano et al., 1995; Shirane et al., 1999) . p21 CIP1 can exert opposing effects on the G 1 -S transition . For example, mitogens stimulate a modest induction of p21 CIP1 , which may facilitate the assembly of cyclin D/CDK4 complexes and promote the G 1 phase progression (LaBaer et al., 1997; Cheng et al., 1999) . However, in response to DNA damage, p53 mediates a strong induction of p21 CIP1 that exceeds an inhibitory threshold, abolishes CDK2 activity and is required for the DNA damageinduced G 1 cell cycle arrest (Vogelstein et al., 2000) .
The mitogen-activated protein kinase (MAPK) signalling pathways play a major role in regulating cell cycle re-entry (Marshall, 1995; Roovers and Assoian, 2000) . Growth factors activate the Ras-regulated Raf-MEK1/2-ERK1/2 cascade and both the duration and strength of ERK activation determines the proliferative response (Marshall, 1995; Woods et al., 1997; Balmanno and Cook, 1999; Cook et al., 1999) . For example, moderate ERK1/2 activation is required for the expression of cyclin D1 and cell cycle re-entry, whereas high-intensity ERK1/2 activation can induce cell cycle arrest or senescence as a result of the high expression of p21 CIP1 (Woods et al., 1997) or p16
INK4a (Zhu et al., 1998) . c-Jun N-terminal kinase (JNK) and p38 are stressactivated protein kinases (SAPKs) that are activated weakly, if at all, by proliferative stimuli but strongly in response to cellular stresses, including many DNA damaging chemotherapeutic drugs (Davis, 2000) . The precise role of the SAPKs in damage-induced cell cycle regulation is unclear as they have been proposed to be both positive and negative regulators of cell cycle progression (Molnar et al., 1997; Wang et al., 1999; Wisdom et al., 1999; Tournier et al., 2000) . Apart from the possible differences in cellular context, this confusion may arise from the inability to separate SAPK activation from cellular damage, which may activate other components involved in cell cycle arrest such as p53 (Vogelstein et al., 2000) .
To resolve this problem we have used a panel of conditional MAP kinase kinase kinase:ER fusions. Activation of DRaf-1:ER* results in selective activation of the ERK1/2 pathway (Woods et al 1997; Weston et al 2003) . Studies indicate that MEKK1 shows selectivity for the JNK pathway (Xia et al., 1998; Yujiri et al., 2000) and we have recently shown that DMEKK1:ER* does indeed selectively activate the JNK pathway . Finally, MEKK3 can activate the ERK, JNK and p38 pathways when overexpressed (Deacon and Blank, 1999) and DMEKK3:ER* exhibits the same selectivity (Garner et al., 2002) . Using this panel of conditional kinases we show that the ERK1/2 and p38 pathways cooperate to cause a sustained G 1 cell cycle arrest, which requires p21 CIP1 expression whereas persistent activation of JNK or ERK alone fails to inhibit the G 1 -S transition.
Results

DMEKK3
:ER* enhances ERK1 activity and induces JNK and p38 activity during serum-stimulated cell cycle re-entry CCl39 fibroblasts expressing DMEKK3:ER* (CM3 cells) or a catalytically inactive variant (CM3.KD cells) were described previously (Garner et al., 2002) . Activation of DMEKK3:ER* by 4-hydroxytamoxifen (4-HT) causes a strong activation of ERK1/2, JNK and p38 in serum-starved cells. However, since we were studying the effect of activating DMEKK3:ER* during serum restimulation of quiescent cells, it was important to determine the effect of activating DMEKK3:ER* under the same conditions. We stimulated quiescent CM3.6 cells with 10% FBS in the presence of 100 nM 4-HT or an ethanol vehicle control and assayed the activation of endogenous ERK1, JNK1 and p38a by immune complex kinase assays. Foetal bovine serum (FBS) caused a robust, sustained activation of ERK1 and this response was only moderately (30%) enhanced by the activation of DMEKK3:ER* (Figure 1a ). In contrast, FBS stimulation caused little or no activation of JNK or p38, whereas FBS þ 4-HT caused a strong and sustained eight-to 12-fold activation of both pathways (Figure 1b) .
Full-length MEKK3 can activate NFkB when overexpressed (Yang et al., 2001 ) so we assayed IkB phosphorylation and degradation as a surrogate marker for NFkB activation. FBS stimulation, with or without 4-HT, had no effect on IkB whereas the phosphatase inhibitor calyculin A, used as a positive control, caused phosphorylation and degradation of IkB ( Figure 1c) ; thus, it is unlikely that DMEKK3:ER* activates NFkB in these cells. These data indicate that activation of DMEKK3:ER* during serum-stimulated cell cycle reentry causes a strong activation of JNK and p38 but only a modest enhancement of ERK1/2 activity. 1 DMEKK3:ER* enhances ERK1/2 activity but strongly activates JNK and p38 during cell cycle re-entry. Quiescent CM3.6 cells were restimulated with 10% FBS for 1, 4 or 8 h in the presence of 0.04% ethanol (vehicle control) or 100 nM 4-HT. (a) Endogenous ERK1 activity was assayed by immune complex kinase assay with MBP as a substrate. (b) Endogenous JNK1 and p38a activities were assayed using GST-c-Jun (JNK) or His-MAPKAP-K2 (p38) as substrates. (c) IkB phosphorylation status was assessed by subjecting whole-cell lysates to Western blot analysis with phospho-IkB or total IkB antibodies; lysates from cells treated with 10 nM calyculin A for 1 h served as a positive control. Results are taken from a single experiment; similar results were observed in a total of three independent experiments Regulation of G 1 -S transition by MAPKs & SAPKs DE Todd et al DMEKK3:ER* induces a sustained G 1 cell cycle arrest
We next examined the consequences of activating DMEKK3:ER* on serum-stimulated cell cycle re-entry in quiescent CM3.6 cells. In control cells, the first peak of FBS-stimulated [ 3 H]thymidine incorporation was observed after 15 h, and was followed by a second round of S phase at 25-30 h (Figure 2a) . In contrast, 4-HT-treated cells exhibited only a slight increase in [ 3 H]thymidine incorporation at 15 h (25% of that seen in ethanol-treated cells) and complete inhibition to the basal level at all other time points. This inhibition of DNA synthesis was dose-dependent: an IC 50 of 5-10 nM was typically observed (data not shown) agreeing well with the EC 50 for the activation of ERK, JNK and p38 in these cells (Garner et al., 2002) . As a specificity control CM3.KD cells, expressing catalytically inactive DMEKK3:ER*, were unaffected by 4-HT (Figure 2b ).
Flow cytometry was used to confirm at what stage in the cell cycle CM3 cells arrested. The majority of serumstarved cells were in G 0 /G 1 , but after 24 h with FBS significant numbers were in S and G 2 . In contrast, cells treated with FBS þ 4-HT arrested predominantly at G 1 ; very few cells were able to pass through the first S phase and reach G 2 /M (Figure 2c ). Similar results were obtained in two other CM3 clones (see also Garner et al., 2002) . Thus, the activation of DMEKK3:ER* prevents FBS-stimulated cell cycle re-entry and CM3 cells arrest in G 1 .
Activation of DMEKK3:ER* promotes p21 CIP1 expression, inhibition of CDK2 and prevents phosphorylation of pRb
We next analysed the expression of cell cycle regulatory proteins involved in the G 1 -S progression. Western blot analysis revealed that activation of DMEKK3:ER* delayed the FBS-stimulated increase in cyclin D1 expression and inhibited both Cdc25A and cyclin A expression, but had little effect on the CDK4 and CDK2 expression or p27 KIP1 degradation (Figure 3a) . A selection of cyclin E antibodies exhibited poor crossreactivity with the hamster equivalent and as a consequence cyclin E protein levels could not be monitored. However, 4-HT treatment did cause a very strong induction of p21 CIP1 expression. Activation of DMEKK3:ER* greatly enhanced the normally modest 
serum-stimulated increase in p21
CIP1 expression at all time points tested (two examples, over different time points, are shown in Figure 3a) . The increase in p21 CIP1 levels was not accompanied by an increase in p53 expression. p53 levels increased in response to FBS stimulation, as seen previously (Reich and Levine, 1984) , and the activation of DMEKK3:ER* actually reduced this increase in p53 levels.
CDK2-associated H1 kinase activity increased rapidly after 12 h of FBS stimulation in two independently derived clones (CM3.3 and CM3.6; Garner et al., 2002) . However, the activation of CDK2 was almost completely abolished when DMEKK3:ER* was activated (Figure 3b , left), and this was accompanied by a 4-HT-dependent recruitment of p21 CIP1 into CDK2 complexes (Figure 3b, right) . Activation of DMEKK3:ER* also inhibited cyclin A-associated kinase activity, and this was also accompanied by the recruitment of p21 CIP1 to cyclin A immuno-precipitates (D. Todd and S Cook, unpublished results). Finally, 4-HT treatment inhibited the FBS-stimulated accumulation of hyper-phosphorylated pRb, and the expression of the related pocket protein p107 (Figure 3a) . Collectively, these data are consistent with DMEKK3:ER* inducing a G 1 arrest by increasing p21 CIP1 levels, inhibiting CDK2 and so preventing the phosphorylation and inactivation of pRb. In such a scenario, the loss of Cdc25A, cyclin A and p107 expression would presumably reflect the fact that they are E2F target genes (Dyson, 1998) .
DMEKK3:ER* fails to increase p21
CIP1 expression and causes only a transient delay in cell cycle re-entry in Rat-1 cells
To investigate the potential role of p21 CIP1 we examined Rat-1 cells, in which the p21 CIP1 promoter is silenced by methylation (Allan et al., 2000) . We have previously shown that DMEKK3:ER* also activates ERK, JNK and p38 in Rat-1 cells (called RM3 cells) (Garner et al., 2002) . Furthermore, control experiments confirmed that activation of DMEKK3:ER* during FBS stimulation of RM3 cells resulted in the same modest enhancement of ERK1 activity and the strong activation of JNK1 and p38a, as seen in CM3 cells (D Todd, K Balmanno and S Cook, unpublished results).
Following FBS stimulation in the presence or absence of 4-HT, we again observed that activation of DMEK-K3:ER* caused a super-induction of p21 CIP1 in CM3 cells whereas RM3 cells were unable to express p21 CIP1 at any time point (Figure 4a ). This lack of p21 CIP1 induction was attributable to DNA methylation, as treatment with 5-Aza-2-deoxycytidine (an inhibitor of DNA methyltransferases) restores p21 CIP1 expression (Allan et al., 2000; Garner et al., 2002) . In control RM3 cells, CDK2-associated kinase activity increased after 12 h of serum stimulation. In contrast to the sustained inhibition of CDK2 activity seen in CM3 cells, 4-HT treatment of RM3 cells caused only a transient 5-10 h delay before CDK2 activation proceeded normally (Figure 4b , left). The delayed induction of CDK2 activity was reflected in the phosphorylation status of pRb, the expression of p107 and cyclin A which all proceeded normally after a delay of several hours in the presence of 4-HT compared to cells treated with FBS alone (Figure 4b , right).
These biochemical changes were in turn reflected in the kinetics of the S phase entry. In 4-HT-treated RM3 cells, the increase in [ These results were confirmed by flow cytometry (Figure 4d ). For example, 4-HT caused a delay in cell cycle re-entry at 20 h, but after 25 h 4-HT-treated cells were progressing through S phase and G 2 and cells with a 4n DNA content represented the largest fraction of the population after 30 h of FBS þ 4-HT (Figure 4d ). This probably reflects the DMEKK3:ER*-induced G 2 arrest that is independent of p21 CIP1 status (Garner et al., 2002) . Thus in contrast to CM3 cells (Figure 2 ), RM3 cells were unable to sustain a DMEKK3:ER*-induced G 1 arrest and ultimately arrested at G 2 .
p21
CIP1 expression is required for the DMEKK3: ER*-induced G 1 cell cycle arrest
To confirm that p21 CIP1 expression was required for the DMEKK3:ER*-induced sustained G 1 arrest we expressed Myc-tagged DMEKK3:ER* in 3T3 cell lines derived from WT or p21 CIP1À/À mouse embryo fibroblasts (Figure 5a (Figure 5c ). In contrast, activation of DMEK-K3:ER* in p21 CIP1À/À 3T3 cells caused only a weak 25-30% inhibition of DNA synthesis indicating that the DMEKK3:ER*-induced G 1 arrest was defective. Flow cytometry confirmed that the p21 CIP1À/À 3T3 cells were defective for the G 1 arrest so that after 24 h of FBS þ 4-HT the majority of cells were in S phase or G 2 (Figure 5d ). Thus, p21
CIP1 is required for a sustained G 1 arrest in response to the activation of DMEK-K3:ER*; in the absence of p21 CIP1 cells can still enter S phase but arrest at G 2 (Garner et al., 2002) .
DMEKK3:ER*-stimulated p21
CIP1 expression requires the ERK1/2 and p38 pathways Pharmacological inhibitors of the ERK1/2 pathway (PD184352, Sebolt-Leopold et al., 1999) and p38 (SB203580, Cuenda et al., 1995) were used to investigate which pathways were responsible for DMEKK3:ER*-mediated p21 CIP1 expression and cell cycle arrest (Figure 6a ). 4-HT-induced p21 CIP1 expression was partially inhibited by treatment with either PD184352 or SB203580 and completely abolished when the two drugs were used in combination. A control blot for phospho-ERK1/2 confirmed that PD184352, but not SB203580, was preventing the activation of ERK1/2 under these conditions. We could only assess the effects of the p38 inhibitor (SB203580) on DMEKK3:ER*-mediated cell cycle arrest as the ERK1/2 pathway inhibitor PD184352 was itself very effective at inhibiting serum-stimulated cell cycle re-entry (Squires et al., 2002) . Following release from quiescence, CM3.3 cells were labelled with (Figure 6b ). In the absence of 4-HT, serum-stimulated DNA synthesis was not affected by SB203580 and this agreed with the lack of effect of SB203580 on the modest serum-stimulated expression of p21 CIP1 (Figure 6c ). Since serum causes little if any increase in p38 activity these results demonstrate that there is no role for p38 in the normal FBS-stimulated expression of p21 CIP1 or cell cycle re-entry. However, SB203580 was able to partially reverse the inhibition of serum-stimulated DNA (Figure 6b) , suggesting that the p38a/ b pathway was required for optimal p21 CIP1 expression and cell cycle arrest induced by activated DMEK-K3:ER*. Control immunoblots (Figure 6d ) confirmed the selectivity of SB203580, which prevented phosphorylation of the p38 substrate, MAPKAP-K2, but did not prevent the phosphorylation of ERK1/2 or c-Jun (a surrogate assay for JNK). CIP1 protein expression within 4 h (Figure 7a , left), which was precisely mirrored by a substantial increase in p21 CIP1 mRNA (Figure 7a , right). In common with CM3 cells, there was no accompanying increase in p53 levels; indeed, HM3 cells failed to express p21 CIP1 expression was also abolished by the combination of PD184352 and SB203580 (Figure 7c ). Since PD184352 selectively inhibits the ERK1/2 pathway (Squires et al 2002) whereas U0126 inhibits both the ERK1/2 and ERK5 pathways (Kamakura et al., 1999) , these results indicate that DMEKK3:ER* promotes the expression of p21 CIP1 mRNA and protein through the combined effects of the ERK1/2 and p38 pathways. Furthermore, this expression of p21 CIP1 is independent of p53 since it takes place in the absence of p53 stabilization and in cells (CCl39 and HEK293) in which p53 appears to be nonfunctional.
Selective activation of the ERK1/2 pathway by DRaf-1:ER* does not induce p21 CIP1 and fails to inhibit the G 1 -S transition Since PD184352 and U0126 both inhibit cell cycle reentry it was not possible to use these drugs to assess the role of the ERK1/2 pathway in the DMEKK3:ER*-induced cell cycle arrest. As an alternative we examined the impact of selective activation of the ERK1/2 on FBS-stimulated cell cycle re-entry. We have previously described CR1-11 cells (Weston et al., 2003) ; these are CCl39 cells stably expressing DRaf-1:ER*, which selectively activates the ERK1/2 pathway, but not JNK, p38 or PKB. When quiescent CR1-11 cells were stimulated with FBS74-HT we observed that activation of DRaf-1:ER* had no effect on the early peak of ERK1 activity but potentiated the smaller sustained phase of ERK1 activity by between 30 and 50% (Figure 8a ). This was slightly greater than the effect of DMEKK3:ER* on FBS-stimulated ERK1 activity (Figure 1a) . However, this was not sufficient to increase p21 CIP1 levels over that seen in response to FBS (Figure 8b ) and did not inhibit FBS-stimulated DNA synthesis (Figure 8c ). CIP1 and fails to inhibit the G 1 -S transition Activation of JNK is frequently associated with stressful stimuli that can cause cell cycle arrest; therefore, we wished to determine what contribution JNK signalling made to the G 1 arrest. To date we have failed to demonstrate significant, reproducible efficacy with the commercially available JNK inhibitor SP600125 (K Balmanno and S Cook, unpublished results). Furthermore, this drug has recently been shown to exhibit poor selectivity (Bain et al., 2003) . Therefore, as an alternative strategy for examining the role of JNK in the G 1 -S transition we used the conditional protein kinase DMEKK1:ER*, which selectively activates the JNK pathway without activating ERK1/2, ERK5, p38, PKB or IkB kinase . For these experiments we used CCl39 and Rat-1 cells stably expressing DMEKK1:ER* (CM1 and RM1 cells respectively).
When quiescent CM1 cells were restimulated with FBS we observed a strong increase in ERK1/2 phosphorylation, whereas p38 was not phosphorylated and FBS caused only a weak increase in phosphorylation of c-Jun, a surrogate assay for JNK (Figure 9a ). When cells were stimulated with FBS þ 4-HT, activation of DMEKK1:ER* caused a striking increase in c-Jun phosphorylation which was apparent within 1 h; quantification of these blots indicated that this increase was Whole-cell lysates were prepared and blotted for expression of p21 CIP1 , p53, P-ERK1/2 and ERK1/2. (Right) Total RNA was prepared and used to assay p21 CIP1 mRNA levels by (Q)RT-PCR. Levels of p21 CIP1 mRNA were normalized to the GAPDH internal control and are expressed as fold increase over basal. In both cases results are shown from a single experiment representative of three. (b) HM3 cells were treated with 10 mM SB203580, 10 mM U0126 and 100 nM 4-HT as indicated. (Left) Whole-cell lysates were prepared and blotted for expression of p21 CIP1 , p53, P-ERK1/2. Results are shown from a single experiment representative of three. (Right) Total RNA was prepared and used to assay p21 CIP1 mRNA levels by (Q)RT-PCR. Levels of p21 CIP1 mRNA were normalized to the GAPDH internal control, expressed as a percentage of the maximum and are pooled from two independent experiments (mean7range). (c) HM3 cells were treated with 10 mM SB203580, 5 mM PD184352 and 100 nM 4-HT as indicated. (Left) Whole-cell lysates were prepared and blotted for expression of p21 CIP1 , p53, P-ERK1/2. Results are shown from a single experiment representative of two of the order of 10-fold over that seen in response to FBS (Figure 9a ). In contrast, DMEKK1:ER* had no effect on ERK1/2 phosphorylation and little, if any, effect on p38. These results show that the selectivity of DMEK-K1:ER* previously described also applies during FBS stimulation. Despite this strong, selective activation of JNK, activation of DMEK-K1:ER* had no effect on FBS-stimulated expression of cyclin D1 or cyclin A (Figure 9b ) or DNA synthesis assayed up to 15 h (Figure 9c) . Thus, activation of JNK does not antagonize the G 1 -S transition in CCl39 cells.
However, in the course of these studies we noted that activation of DMEKK1:ER* delayed the progress of cells to the second round of DNA synthesis at 25-30 h (Figure 9c ). Since activation of JNK did not delay the G 1 -S transition per se, we reasoned that it might be exerting an effect elsewhere in the cell cycle. Indeed, flow cytometric analysis of CM1 cells revealed that activation of DMEKK1:ER* caused cells to accumulate at G 2 with a 4n DNA content (Figure 9d ), though this effect was not observed with a catalytically inactive variant of DMEKK1:ER* (KD in Figure 9d) . Identical results were observed in RM1 cells. For example, activation DMEKK1:ER* caused a strong, 18-fold activation of JNK but had little effect on ERK1 or p38 (Figure 9e ). Despite this, activation of DMEKK1:ER* failed to inhibit the G 1 -S in RM1 cells (Figure 9f ) though it did delay progression through to the second S phase.
Previous studies have suggested that JNK-dependent phosphorylation can stabilize p53 (Fuchs et al., 1998; Buschmann et al., 2001) . Since CCl39 cells lack functional p53 and Rat-1 cells fail to express p21 CIP1 (the major p53 target involved in the G 1 checkpoint) it was important to examine the effect of DMEKK1:ER* in a cell line that contained wild-type p53 and p21. Accordingly we expressed Myc-DMEKK1:ER* in the HCT116 colorectal cancer cell line (Figure 10a ). Control Figure 9 Selective activation of the JNK pathway by DMEK-K1:ER* does not induce p21 CIP1 and fails to inhibit the G 1 -S transition in CM1 and RM1 cells. (a) Quiescent CM1 cells (CCl39 cells expressing DMEKK1:ER*) were stimulated with 10% FBS7100 nM 4-HT for the times indicated or were treated with or without 50 mM sodium arsenite (NaAs) for 1 h. Whole-cell lysates were immunoblotted with antibodies specific for P-ERK1/2, P-p38, P-c-Jun and total ERK1/2 (as a loading control). (b and c) Quiescent CM1 cells were stimulated with 10% FBS7100 nM 4-HT for the times indicated and (b) whole-cell lysates were immunoblotted with antibodies specific for cyclin D1, cyclin A, CDK2 and p21 CIP1 or (c) cells were assayed for [ studies confirmed that these HCT116-M1 cells exhibited stabilization of p53, expression of p21 CIP1 and G 1 arrest in response to doxorubicin (Garner et al. 2002; C Newson, K Balmanno and S Cook, unpublished observations) . Treatment of HCT116-M1 cells with 4-HT had no effect on the phosphorylation of ERK1/2 or p38 but caused a strong phosphorylation of c-Jun confirming that the DMEKK1:ER* was functional and selective. Furthermore, the magnitude of JNK activation was comparable to that seen with many commonly used stress agonists (Figure 10b ). Despite this, DMEK-K1:ER* had no effect on the expression of p53 and p21 CIP1 expression (Figure 10a ) or FBS-stimulated DNA synthesis in HCT116-M1 cells (Figure 10c ). In contrast, both PD184352 and doxorubicin inhibited DNA synthesis; the latter confirming that the DNA damage-induced G 1 checkpoint was intact in these cells. Thus, these results show that selective and persistent activation of the JNK pathway fails to inhibit the G 1 -S transition even in cells with an intact p53-p21 CIP1 pathway.
Discussion
In order to analyse the effects of MAPK or SAPK activation on cell cycle re-entry we felt that it was important to stimulate these pathways in the absence of cellular damage that might activate other cell cycle arrest pathways. The panel of kinase:ER* fusions used here appears to fulfil this aim. During FBS stimulation DRaf-1:ER* selectively enhances ERK1/2 activation, DMEKK1:ER* selectively activates JNK while DMEK-K3:ER* enhances ERK1/2 but strongly activates JNK and p38. In the case of DMEKK1:ER* and DMEK-K3:ER* we have previously shown that the magnitude of JNK and/or p38 activation is similar to that seen in response to either anisomycin or UV (Garner et al., 2002; Molton et al., 2003) . These constructs should not be considered as mimetics of the corresponding full-length kinases but simply afford rapid, conditional, titratable activation of defined MAPK or SAPK pathways without overexpression or overt cellular stress. Using these systems we have shown that ERK1/2 and p38 cooperate to inhibit the G 1 -S progression by at least two discrete mechanisms: a sustained p53-independent arrest that requires p21 CIP1 expression and a more transient delay that is independent of p21 CIP1 . In CM3 cells activation of DMEKK3:ER* induced a strong increase in p21 CIP1 expression, inhibition of CDK2 and DNA synthesis (Figure 2 and 3) . In contrast, in RM3 cells, in which the p21 CIP1 promoter is silenced by methylation, activation of DMEKK3:ER* failed to increase p21 CIP1 expression and caused only a delay in cell cycle re-entry. While these results were compelling, they did not provide proof of the requirement for p21 CIP1 . However, the demonstration that p21 CIP1À/À 3T3 cells were defective in their G 1 arrest in response to the activation of DMEKK3:ER* compared to their wildtype counterparts confirmed that p21 CIP1 expression is required for DMEKK3:ER* to induce a sustained G 1 arrest.
Our results differ fundamentally from a study in NIH3T3 cells using a related construct, MEKK3-ER, which failed to increase p21 CIP1 expression (EllingerZiegelbauer et al., 1999) . This is unlikely to represent a cell type-specific difference as we have observed p21 CIP1 induction in CM3 cells, HEK293 cells and 3T3-immortalized MEFs. A more likely explanation may be the way the experiments were performed. In NIH3T3 cells, MEKK3-ER was activated for 4 days in serumfree conditions before restimulating with FBS. In our own studies we have found that the expression of p21 CIP1 is rapid (within 4 h) and maximal by 24 h; however, p21 CIP1 levels then decline, probably due to the substantial apoptotic response observed from approximately 24 h onwards in all cells that we have examined to date (C Weston and S Cook, unpublished observations). Thus, by activating MEKK3-ER for 4 days rather than the detailed time courses employed here the previous study may simply have missed the increase in p21 CIP1 expression. Certainly, they did not examine the requirement for p21 CIP1 .
In the absence of p21 CIP1 , RM3 cells progressed through G 1 and entered S phase in the presence of 4-HT, albeit with delayed kinetics (Figure 4) ; similar results were observed in the p21 CIP1À/À 3T3 cells ( Figure 5) . Thus, the activation of DMEKK3:ER* can clearly delay cell cycle re-entry via a p21 CIP1 -independent mechanism. In CM3 cells activation of DMEKK3:ER* was able to reduce the FBS-stimulated expression of cyclin D1 and Cdc25A ( Figure 3 ) and a similar effect was observed in the RM3 cells (D Todd and S Cook, unpublished observations). Impaired expression of cyclin D1 and/or Cdc25A would both seem to be plausible mechanisms for a p21 CIP1 -independent delay in S phase entry by preventing the activation of CDK4, CDK2, pRb phosphorylation and the subsequent induction of E2F-responsive genes (Jinno et al., 1994; Schulze et al., 1995; Geng et al., 1996; Blomberg and Hoffmann, 1999) . p21 CIP1À/À mouse embryo fibroblasts still exhibit some degree of p21 CIP1 -independent G 1 arrest in response to DNA damage (Brugarolas et al., 1995 , Deng et al., 1995 and recent reports have suggested that the p53-dependent upregulation of p21 CIP1 is too slow to account for the rapid cell cycle block seen in response to DNA damage. Alternative mechanisms proposed for a rapid p53-independent initiation of G 1 arrest include the proteasome-dependent destruction of either cyclin D1 (Agami and Bernards, 2000) or Cdc25A (Mailand et al., 2000) before the slower p53-dependent induction of p21 CIP1 ensures a sustained G 1 arrest. Activation of DMEKK3:ER* may trigger similar mechanisms to elicit a sustained G 1 arrest, although p21 CIP1 induction may be p53-independent in our system (see below). Activation of p38 has been shown to inhibit the transcription of cyclin D1 (Lavoie et al., 1996) and to increase the turnover of the cyclin D1 protein (Casanovas et al., 2000) , and future studies will aim to elucidate the mechanism by which activation of DMEKK3:ER* downregulates cyclin D1 and Cdc25A expression.
ERK1/2 and p38 cooperate to promote a p53-independent expression of p21
CIP1
Selective pharmacological inhibitors of the ERK1/2 pathway (PD184352) or of p38 (SB203580) revealed for the first time that ERK1/2 and p38 cooperate to induce p21 CIP1 expression. The requirement for the ERK1/2 pathway in the DMEKK3:ER*-dependent expression of p21 CIP1 is reminiscent of the response seen with DB-Raf:ER* (Woods et al., 1997; Park et al., 2000) . However, the role of the ERK1/2 pathway in the DMEKK3:ER*-induced cell cycle arrest has proved difficult to resolve because MEK1/2 inhibitors inhibit cell cycle re-entry per se (for example see Balmanno and Cook, 1999; Squires et al., 2002) . In CR1-11 cells, activation of DRaf-1:ER* caused a similar enhancement of serum-stimulated ERK1 activity, but this did not increase p21 CIP1 expression or cause a G 1 arrest (Figure 8) . A role for p38 in the expression of p21 CIP1 is not entirely without precedent. Some stresses or cytokines can increase p21 CIP1 expression in a p38-dependent fashion, acting at the transcriptional level (Ussat et al., 2002) or by promoting stabilization of the p21 CIP1 mRNA (Wang et al., 2000) or p21 CIP1 protein (Kim et al., 2002) . We have shown that DMEKK3:ER* can induce a substantial increase in p21 CIP1 mRNA and protein in HEK293 cells and both protein and mRNA expression is abolished by the combination of ERK1/2 and p38 pathway inhibitors, underscoring the reproducibility of this novel cooperation between the ERK1/2 and p38 pathways (Figure 7 ). Whether this represents an increase in transcription or mRNA stability remains to be determined.
There is a pre-eminent role for p53 in stress-induced p21 CIP1 expression (Kastan et al., 1991; El-Deiry et al., 1993; Tishler et al., 1993; Waldman et al., 1995; Vogelstein et al., 2000) but while p53 has been linked to the MAPKs/SAPKs (Bulavin et al., 1999; Fuchs et al., 1998; Persons et al., 2000; Sanchez-Prieto et al., 2000; She et al., 2000) p53 is unlikely to be involved in DMEKK3:ER*-dependent p21 CIP1 expression. For example, activation of DMEKK3:ER* did not cause stabilization of p53 in CM3 or HM3 cells (Figure 3  and 7) . Furthermore, while CM3 cells express immunereactive p53, it seems to be nonfunctional since the protein is not stabilized by DNA damage and CM3 cells fail to express p21 CIP1 or arrest at G 1 following DNA damage (Garner et al., 2002) ; the same applies to p53 in HM3 cells (R Densham and S Cook, unpublished observations). The ERK1/2 pathway can induce p21 CIP1 expression by p53-dependent and independent pathways (McMahon and Woods, 2001) . While the strong activation of ERK1/2 seen with DB-Raf:ER* may be sufficient for the strong expression of p21 CIP1 and cell cycle arrest (Woods et al., 1997) , the more modest levels of ERK1/2 activity attained here with DRaf-1:ER* or DMEKK3:ER* may require cooperation from other pathways, such as p53 (missing in CCl39 and HEK293 cells) or p38 (provided by DMEKK3:ER* but not DMEKK1:ER*), to induce growth inhibitory levels of p21 CIP1 .
Activation of JNK by DMEKK1:ER* fails to inhibit the G 1 -S transition Interestingly, no obvious role for the JNK pathway in regulating the G 1 -S transition emerges from this study. We tried using the 'JNK inhibitor' SP600125 to see if JNK was required for the effects of DMEKK3:ER* but doses of up to 30 mM were required to cause even a partial reduction in c-Jun phosphorylation and resulted in the inhibition of DNA synthesis and induction of apoptosis (K Balmanno and S Cook, unpublished results), perhaps reflecting the nonspecific nature of this molecule (Bain et al., 2003) . As an alternative strategy we used DMEKK1:ER*, which selectively activates the JNK pathway . In three different cell lines, sustained JNK activation failed to inhibit FBS-stimulated cell cycle re-entry; this included HCT116 cells, which possess a functional p53-p21 CIP1 pathway. While this conflicts with the notion that JNKdependent phosphorylation stabilizes p53 (Fuchs et al., 1998) it may simply mean that JNK alone is not sufficient to activate p53. For example, both JNK and p38 have been shown to phosphorylate p53, allowing binding of the peptidyl-prolyl isomerase Pin1 (Zacchi et al., 2002) and their combined effects may be important for the activation of p53. Alternatively, JNK-dependent regulation of p53 may be linked to the proapoptotic functions of p53 but not its cell cycle arrest function. Indeed, Jnk1
À/À Jnk2 À/À MEFs exhibit a proliferative defect but still undergo a G 1 arrest in response to DNA damage (Tournier et al., 2000) , suggesting that JNK is required for normal cell proliferation but not for a p53-mediated G 1 cell cycle arrest. Our results with DMEKK1:ER* are perhaps more in accord with this model. Activation of JNK by DMEKK1:ER* did delay completion of the cell cycle after the S phase, causing arrest at G 2 /M, and future studies should aim to address how JNK interacts with the G 2 checkpoint machinery.
To conclude, we have used conditional protein kinases as a means of activating defined MAPK and SAPK signalling pathways in the absence of cell stress. Activation of DMEKK3:ER* mimics the DNA damage response by inhibiting the G 1 -S progression by two kinetically distinct mechanisms. Our data suggest that the ERK1/2 and p38 pathways cooperate to promote p21 CIP1 induction and this is necessary to ensure a sustained G 1 cell cycle arrest, whereas the more transient delay may reflect the inhibition of Cdc25A and cyclin D1 expression. In contrast, selective activation of the JNK pathway fails to impact on cell cycle re-entry. It is hoped that the combined use of a selection of kinase:ER* fusions and pharmacological inhibitors will help to further define the role of individual MAPK and SAPK signalling cassettes in regulating the G 1 -S transition.
Materials and methods
Materials
4-HT was purchased from Sigma, SB203580 and PD184352 were from Calbiochem. 4-HT was prepared as a 1 mM stock in ethanol and stored at À70 1 C. SB203580 (2 mM) and PD184352 (20 mM) were made up in DMSO and stored at À201C. Foetal bovine serum (FBS) and all other cell culture reagents were from Gibco Life Technologies. The following antibodies were used: Myc tag antibody (9E10); CDK2 (sc-163), CDK4 (sc-260), Cdc25A (sc-7389), cyclin E (sc-481) and p107 (sc-318) were from Santa Cruz; cyclin D1 (CC12) and p27
Kip1 (NA35) from Calbiochem; cyclin A (MS-384-P) and p53 (MS-104-P) from Neo Markers; p21 Cip1 (556431) from Pharmingen; Rb Cterminal control antibody (9302), phospho-IkB (9241), IkB (9242), MAPKAP-K2 (3042), phospho-MAPKAP-K2 (3044) and phospho-ERK1/2 (9106) were from Cell Signalling Technology. Horseradish peroxidase-conjugated secondary antibodies were from Bio-Rad, and detection was with the enhanced chemiluminescence (ECL) system (Amersham). Protease inhibitors were from Sigma. All other reagents were of the highest grade commercially available.
Cells, cell culture and cell synchronization
CCl39 and Rat-1 cells expressing DMEKK3:ER* (CM3 and RM3 respectively) were described previously (Garner et al., 2002) . WT and p21 CIP1À/À 3T3 cells, provided by Amer Mirza and Martin McMahon (UCSF Cancer Centre), were infected with ecotropic retrovirus generated by packaging pBABEPuro-DMEKK3:ER* through BOSC23 cells, followed by selection in 2 mg/ml puromycin. HM3 cells were derived by transfecting HEK293 cells with pBABEPuro-DMEKK3:ER* followed by limiting dilution, selection in 2 mg/ml puromycin and ring cloning. CCl39 cells expressing DRaf-1:ER* (CR1-11 cells) or DMEKK1:ER* (CM1 cells) were described previously Weston et al., 2003) . HCT116-M1 cells expressing DMEKK1:ER were derived by infecting with amphotropic retrovirus generated by packaging pBABEPuro-DMEKK1:ER* through Phoenix-Ampho cells; experiments were performed on a cell line derived from pools of drugresistant cells. All cells were maintained in Dulbecco's modified Eagle medium DMEM (w/o phenol red) supplemented with glutamine, penicillin-streptomycin, 10% (v/v) FBS and 2 mg/ml puromycin. Cells were synchronized (G 0 /G 1 ) by placing in serum-free DMEM for 20 h. The quiescent cells were stimulated to re-enter the cell cycle by addition of 10% FBS in the presence or absence of 4-HT; 0.04% (v/v) ethanol served as a vehicle control.
Preparation of cell lysates, Western blotting and assay of ERK, JNK, p38 and CDK2 kinase activities These were performed as described previously (Balmanno and Cook, 1999; Garner et al., 2002; Weston et al., 2003) . All cell extracts were normalized for cell protein content before proceeding to appropriate assays. For kinase assays phosphorylation signals were analysed using a phosphorimager and are expressed as radioactivity incorporated into appropriate substrate in phosphorimager units.
Real-time RT-PCR
Preparation of total RNA was performed as described previously (Weston et al., 2003) . RT-PCR was performed according to the protocol supplied with the Taqman s Reverse Transcription reagents (Applied Biosystems) as described previously (Weston et al., 2003) . For human p21 CIP1 we used 5 0 -CCAGGTGGACCTGGAGACTCT-3 0 as the forward primer and 5 0 -GGCTTCCTCTTGGAGAAGATCAG-3 0 as the reverse primer. For human GAPDH we used 5 0 -AACAGCCT-CAAGATCATCAGCAA-3 0 as the forward primer and 5 0 -CATGAGTCCTTCCACGATACCAA-3 0 as the reverse primer. Values for p21 CIP1 were normalized to those for GAPDH.
Flow cytometry and assay of DNA synthesis
For analysis of cell cycle re-entry, quiescent cells were stimulated with 10% FBS in the presence of 100 nM 4-HT or 0.04% ethanol (vehicle control). At the indicated times, the cells were trypsinized, stained with propidium iodide (50 mg/ ml) and analysed by flow cytometry using a FACSCalibur flow cytometer (Becton Dickinson) as described previously (Garner et al., 2002) . [
